If that don't get your attention here you need to check your pulse.
“It did show that patients who received lenzilumab had a remarkable reduction in the need for a ventilator or death,” Robinson said. It also showed that they left the hospital in half the time compared with patients who received the standard of care, he said.
The St. David’s sites have enrolled between 15 and 20 people in this study, Robinson said. It’s a blind study, meaning Robinson has no idea which patients received the medication and which got a placebo.
What he has already seen in the patients enrolled is “some patients seem to recover pretty darn quickly,” he said. “That we haven’t seen in other patient populations. There is promise for this therapy. We just don’t know yet.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.